Insider Cluster (2 insiders) ·Filed Jul 6, 2026

IBRX

ImmunityBio, Inc.
NEUTRAL
Impact 2/10
Horizondays Processed2mo ago
Insider cluster: 2 insiders, $1.3M total
Actionable Insight • Neutral

The insider sales are negligible relative to company size and involve only directors, not executives. No bearish signal here. Monitor for any C-suite open-market sales or a material increase in volume that would exceed 0.1% of market cap.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
IBRX ▼ -0.90% at T+60d
NEUTRAL call ✗ call lost -0.90% · α vs SPY -2.62% · entry $8.91 → $8.83
Entry anchored
Jul 2, 03:59 PM ET
via exchange tick
T+1d
-1.68%
call -1.68% · α -1.21%
$8.76
settled 3mo ago
T+5d
-7.74%
call -7.74% · α -8.23%
$8.22
settled 3mo ago
T+20d
-19.53%
call -19.53% · α -18.96%
$7.17
settled 2mo ago
T+60d
-0.90%
call -0.90% · α -2.62%
$8.83
settled 4d ago

Price Chart

Loading chart...

Executive Summary

Two directors of ImmunityBio sold a combined ~$2.7M in open-market stock this week, following derivative exercises. The total sales represent only ~0.027% of the company's $9.9B market cap, making the cluster economically trivial and routine. No C-suite insiders participated, and the pattern suggests standard tax-related diversification rather than informed selling.

Key Financial Metrics

Direction
selling
Total Value
$2.7M
Insiders
2

Key Facts

  • Director Cheryl Cohen sold 131,210 shares at ~$9.50 for $1.25M on 2026-07-02
  • Director Christobel Selecky sold 159,478 shares at ~$9.02 for $1.44M on 2026-07-01, plus 1,000 shares at $9.00 for $9K on 2026-06-30
  • Total open-market sales: ~$2.7M, or 0.027% of market cap
  • Both directors exercised derivative securities (options) prior to selling, a common pattern for tax withholding
  • No C-suite officers (CEO, CFO, etc.) were involved in any trades

Financial Impact

Total insider sales of approximately $2.7M, representing 0.027% of the company's $9.9B market capitalization

dilutioninsider ownership

Risk Factors

  • No material risk from this cluster given the small size and non-executive participation

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-IBRX-1783408251596
7 reports for IBRX
Performance horizon
67% Hit rate 2 of 3 directional calls best @ T+60▲ +19.12%Apr 9, 2026
Filters
Rows
Reports for IBRX — sortable, filterable
TypeNow
Aug 4, 2026
8w ago
8-K
NEUTRAL ★ 5/10
$6.95 $7.87▲ +13.24%▲ +14.48%$10.28 (+47.99%)
Jul 6, 2026
12w ago
Insider Cluster
NEUTRAL ★ 2/10
$8.91 $7.17▼ −19.53%▼ −18.96%$10.28 (+15.43%)
Jul 1, 2026
13w ago
Insider Cluster
NEUTRAL ★ 2/10
$9.20 $6.83▼ −25.76%▼ −23.58%$10.28 (+11.79%)
May 18, 2026
19w ago
8-K
BULLISH ★ 5/10
$7.76 $6.99▼ −9.92%▼ −10.91%$10.28 (+32.54%)
Apr 9, 2026
25w ago
8-K
BULLISH ★ 8/10
$7.48 $8.38▲ +12.03%▲ +4.46%$10.28 (+37.50%)
Apr 6, 2026
25w ago
8-K
NEUTRAL ★ 4/10
$7.08 $7.43▲ +4.94%▼ −4.04%$10.28 (+45.27%)
Feb 28, 2026
30w ago
Institutional Cluster
BULLISH ★ 6/10
$10.44 $6.66▼ −36.21%▼ −28.27%$10.28 (−1.48%)
Showing 7 of 7

US Market Status

Market Closed — Opens Mon (65h 8m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Jul 7, 2026